Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EpigenomeProgramming

Financiado

An experimental and bioinformatic toolbox for functional epigenomics and its app...

An experimental and bioinformatic toolbox for functional epigenomics and its application to epigenetically making and breaking a cancer cell Epigenetic alterations can be detected in all cancers and in essentially every patient. Despite their prevalence, the concrete functional roles of these alterations are not well understood, for two reasons: First, cancer samples t... ver más

30/11/2021

CEMM FORSCHUNGSZE...

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

CEMM FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZ... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-11-30

ERC-StG-2015: ERC Starting Grant

I+D

Cerrada hace 9 años

0% 100% 100%

2 Participantes

CEMM FORSCHUNGSZENTRUM FUER...

1.28M€ | Lider

LEGRAND GROUP ESPANA

1.09M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RTI2018-094009-B-I00 DETERMINANTES DE LA ESTRUCTURA EPIGENOMICA LATENTE EN CANCER... 182K€ Cerrado

SAF2009-08663 CARACTERIZACION EPIGENOMICA DE LAS NEOPLASIAS HEMATOLOGICAS 114K€ Cerrado

PID2021-125282OB-I00 USO DE APROXIMACIONES DE CELULA UNICA PARA DECIFRAR LA EPIGE... 472K€ Cerrado

BFU2011-27658 LA ABERRACION DE LA IMPROMTA GENOMICA EN CANCER, UN EVENTO D... 128K€ Cerrado

RTI2018-094049-B-I00 DISRUPCION EPIGENETICA Y GENETICA DE LAS MODIFICACIONES DEL... Cerrado

MACHETE Unraveling the Functional Complexity of Cancer Genomes throu... 2M€ Cerrado

Duración del proyecto: 67 meses Fecha Inicio: 2016-04-26
Fecha Fin: 2021-11-30

Líder del proyecto

CEMM FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZ... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Descripción del proyecto Epigenetic alterations can be detected in all cancers and in essentially every patient. Despite their prevalence, the concrete functional roles of these alterations are not well understood, for two reasons: First, cancer samples tend to carry many correlated epigenetic alterations, making it difficult to statistically distinguish relevant driver events from those that co-occur for other reasons. Second, we lack tools for targeted epigenome editing that could be used to validate biological function in perturbation and rescue experiments. The proposed project strives to overcome these limitations through experimental and bioinformatic methods development, with the ambition of making and breaking cancer cells in vitro by introducing defined sets of epigenetic alterations. We will focus on leukemia as our model cancer (given its low mutation rate, frequent defects in epigenetic regulators, and availability of excellent functional assays), but the concepts and methods are general. In Aim 1, we will generate epigenome profiles for a human knockout cell collection comprising 100 epigenetic regulators and use the data to functionally annotate thousands of epigenetic alterations observed in large cancer datasets. In Aim 2, we will develop an experimental toolbox for epigenome programming using epigenetic drugs, CRISPR-assisted recruitment of epigenetic modifiers for locus-specific editing, and cell-derived guide RNA libraries for epigenome copying. Finally, in Aim 3 we will explore epigenome programming (methods from Aim 2) of candidate driver events (predictions from Aim 1) with the ultimate goal of converting cancer cells into non-cancer cells and vice versa. In summary, this project will establish a broadly applicable methodology and toolbox for dissecting the functional roles of epigenetic alterations in cancer. Moreover, successful creation of a cancer that is driven purely by epigenetic alterations could challenge our understanding of cancer as a genetic disease.

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores